US $65 million of Fudan University's patent for immunooncology drugs was transferred to Huya

On March 15, Professor Yang Qing of School of life sciences of Fudan University and vice president Jin Li of Fudan University reached an agreement in Shanghai between Fudan University and Huya (Shanghai Asia) Company of the United States Professor Yang Qing of School of life sciences of Fudan University granted Huya company of the United States a paid license of IDO inhibitors with independent intellectual property rights for tumor immunotherapy The transfer will bring as much as $65 million to Fudan University and Professor Yang Qing It is understood that Ido inhibitors, as drugs with new drug targets and new mechanisms, can be used to treat tumor, Alzheimer's disease, depression, cataract and other major diseases, with broad social and economic benefits At present, the market prospect of IDO inhibitors in foreign pharmaceutical industry is quite promising, and many well-known foreign pharmaceutical companies have announced to join the competition of research and development of IDO inhibitors However, the existing Ido inhibitors generally have low inhibitory effect, and no Ido inhibitors have been published Up to now, the related compounds developed by new L ink genetics and Incyte have entered the clinical trial stage The new type of IDO inhibitor led by Yang Qing has applied for domestic patent and PCT international patent, and is expected to be the third one to enter the clinical experimental study It is reported that after the signing of the agreement, Huya will pay a certain amount of down payment to Fudan University If the Ido inhibitor obtained excellent results in clinical trials abroad, was successfully listed in the European Union, the United States and Japan, and the annual sales reached different goals, Huya company of the United States would pay Fudan University milestone payments of no more than 65 million US dollars in total "It can be said that $65 million is a considerable price." Yi Baxian, vice president of China Pharmaceutical Industry Research Institute, told surging news reporters that the cooperation between Fudan University and Huya has set a good example for domestic universities and scientific research institutions Yi said that compared with the more mature mode of combination of production, learning and research abroad, there is a bottleneck in the mode of domestic universities and research institutions transferring research patents to foreign countries The most significant problem is that the valuation of innovative drugs in the research phase can not be solved "Because there are no professional institutions engaged in such valuation in China, and there is not enough funds to establish such professional departments in scientific research institutions In other words, the degree of marketization of our research institutions is too low, which makes the domestic research often not recognized or low valuation in the foreign market " Yi said "In the past, European and American countries have been leading in the field of innovative drug research at home, and there are few cases of domestic patent export to foreign countries." Beijing Dingchen medical management consulting center founder Shi lichen told reporters He said that innovative drug research and development is a process with large investment, high risk and long cycle For a long time in the past, basic research and high-end research in the field of innovative drugs in China have been relatively weak, coupled with the long approval procedures after the research and development of new drugs in China, and it is necessary to enter the hospital through bidding The enthusiasm of enterprises for the development of independent innovative drugs is not high, and the domestic drugs in the market are mainly generic drugs With the launch of major national science and technology projects, domestic enterprises and research institutions began to increase investment in independent research and development of innovative drugs Yi Baxian revealed that in the past 7 or 8 years, the number of innovative drugs with independent intellectual property rights in China has reached more than 30, and more and more domestic pharmaceutical enterprises and scientific research institutions have delivered drugs and patents to foreign markets At present, domestic new drugs with independent intellectual property rights are entering an explosive growth period On February 26, Liu Qian, deputy director of the national health and Family Planning Commission, introduced at the national health and family planning work conference that during the 12th Five Year Plan period, the number of new drugs with independent intellectual property rights in China was three times of the total in the previous 50 years; among them, 139 varieties obtained clinical approval documents, 12.5 times more than during the 11th Five Year Plan period More than 200 kinds of drugs have been improved and the accessibility of clinical medication has been improved Ido inhibitors (1) carried out the research and development of IDO inhibitors Since 2006, the research and development of IDO inhibitors has made a good foundation, applied for and included all Chinese invention patents of IDO inhibitors with Chinese intellectual property rights (200910047739.7; 201010134217.3; 201010156427.2; cn 200810204041.7); published several SCI papers on Ido inhibitors (Eur J Med Chem, 2011, 46: 5680-7); J Alzheimer's dis 2010; 22:257-66), etc., which is the only SCI paper about Ido inhibitors in China (2) an Ido inhibitor screening platform was established Ido enzyme has not been commercialized, which results in the delay in the screening of domestic Ido inhibitors Using genetic engineering, the research group expressed and purified recombinant human Ido enzyme, established enzyme activity detection system and Ido inhibitor screening platform (3) a new and efficient Ido inhibitor was obtained The inhibitive effect of the obtained Ido inhibitor is much higher than that of 1-methyltryptophan, which is a general-purpose Ido inhibitor in vivo and in vitro The inhibitive constant reaches the nanomolar level, and it also shows excellent inhibitive activity at the cell level (4) it was found that Huanglian Jiedu Decoction, a traditional Chinese medicine with the therapeutic effect of Alzheimer's disease, had the inhibitory effect on Ido, provided a new molecular mechanism for Huanglian Jiedu Decoction, and provided a new idea for the treatment of Alzheimer's disease The prospect of IDO promotion and Application Ido has been proved to be an important drug discovery target As a new drug target and new mechanism drug, Ido inhibitor can treat many major diseases such as tumor, Alzheimer's disease, depression, cataract, etc its application prospect is very broad, and it can produce huge social and economic benefits The research of this project belongs to the field of medicine In addition to its basic research value and academic significance, its achievements can be transferred to relevant pharmaceutical companies for further research and development According to who statistics, over 7 million people die of cancer every year in the world in the past few years, which is very close to the number of people who die of acute cardiovascular disease In this case, the world anti-tumor drug market is growing rapidly The head of the International Monetary Fund predicts that the global anti-cancer drug market will grow at an annual rate of 15%, which is much higher than that of other drugs; in the next few years, China will become one of the fastest-growing anti-tumor drug markets in the world On the other hand, Alzheimer's disease has become the fourth major cause of death for the elderly With the aging of the world, 20 years later, the number of Alzheimer's patients will change from 35 million to 65.7 million At present, there are 6 million people with Alzheimer's disease in China, accounting for one third of the total number of patients in the world Each year, there are about 1.8 million new cases and 1.056 million deaths The global market for Alzheimer's drugs has grown from $3 billion in 2005 to $5.5 billion in 2009, and will grow at an alarming rate in the future In the above context, it is of great value to study the relationship between IDO and major diseases such as cancer and Alzheimer's disease for revealing the pathogenesis of these diseases It is of great social benefit to propose reasonable and effective treatment strategies and reduce the burden of the government, medical institutions and individuals At the same time, Ido inhibitors, as a kind of molecular targeted drugs based on new targets, have new mechanisms, and have great market potential As an immunosuppressive enzyme, the advantages of IDO in drug safety and stability can not be ignored, which greatly improves its market competitiveness At the same time, the implementation of the project also contributes to leading the research and development of IDO inhibitors in China and improving the research level and strength in the field of IDO inhibitors in China Yang Qing, Ph.D., Professor, School of life sciences, Fudan University, doctoral supervisor Graduated from Hokkaido University in Japan in 2000 with a doctor's degree After that, he worked in Japan's Gifu University and Tokyo University for postdoctoral research and returned to China in 2006 Shanghai Pujiang talents, director of Shanghai Society of Biochemistry and molecular biology, member of biochemical medicine professional committee of Shanghai Pharmaceutical Association J Associates editor, mini Rev Med Chem magazine invited reviewer He has successively presided over projects such as the National Natural Science Foundation of China, Shanghai Pujiang talent plan, key biomedical projects of Shanghai, research start-up fund for returned overseas students, etc He has been engaged in the research and teaching of Biochemistry and pharmaceutical chemistry for a long time, using biochemical, pharmaceutical chemistry, molecular pharmacology and other means to study the molecular mechanism of disease occurrence and research and development of related drugs We focused on the study of the relationship between the disorder of IDO (indoleamine-2,3 dioxygenase) metabolic pathway and diseases, and screened the Ido inhibitors and the corresponding signal transduction network